Onalabs creates a subsidiary in Andorra to apply the sensory bioengineering of its non-invasive digital devices to healthcare and sport

Comunicació,


Onalabs Inno-Hub, the biotech start-up that transforms the skin into a data platform, has taken a further step in its growth and internationalisation with the creation of the Andorran subsidiary Onalabs-AD Digital Health. Through it, and thanks to the support of Andorra Research and Innovation (ARI), it will immediately start two pilot programme, aimed at the areas of sport and health.

The two pilots will be launched simultaneously and will be developed during the first quarter of 2023. In the first of the pilots, which is being promoted jointly with the Andorran Health Care Service (SAAS), the Hospital Nostra Senyora de Meritxell, the Ona Vital device will provide real-time post-operative monitoring of patients with vascular pathologies.

For the second pilot, Onalabs and the Clúster de l'Esport d'Andorra have designed the programme aimed at the world of sport so that athletes, clubs, federations and the Centre de Tecnificació Esportiva d'Ordino can use the different functionalities and applications of the Ona Sport device. The aim is to obtain parameters that improve the performance of athletes and prevent possible future injuries.

"Onalabs-AD Digital Health, a company wholly owned by Onalabs Inno-Hub, is a very important strategic commitment because it makes it possible for us to position ourselves in the Life Sciences and Health sector, to carry out pilot programmes at a national level and to showcase our digital technology on an international level. This is a situation that favours and boosts the commercialisation of our devices, which we have already put in place," says Del Valle, CEO of Onalabs.

The company already has around a hundred potential clients in the medical and sports fields, with sales by 2023 expected to reach around 10,000 devices and a turnover equivalent to 3 million euros.

Onalabs, founded in December 2016 by Elisabet del Valle and Xavier Muñoz, CEO and scientific consultant of the company, respectively, has so far achieved investments of more than 1.5 million euros. The first round, of 250,000 euros, was closed last July in the framework of the Andorra Business Market organised by Andorra Business. The company is preparing its next listing on the BME, although no date has yet been set.

Comments


To comment, please login or create an account
Modify cookies